Anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
18q deletion syndrome Acrodermatitis enteropathica Acrogeria (Gottron syndrome) Acrokeratosis verruciformis (acrokeratosis verruciformis of Hopf) Adams–Oliver syndrome Adducted thumbs syndrome Albright's hereditary osteodystrophy Angelman syndrome Apert syndrome (acrocephalosyndactyly) Arthrogryposis–renal dysfunction–cholestasis syndrome Ataxia telangiectasia (Louis–Bar syndrome) Atrichia with papular lesions (papular atrichia) Atrophodermia vermiculata (acne vermoulante, acne vermoulanti, atrophoderma reticulata symmetrica faciei, atrophoderma reticulatum, atrophoderma vermiculata, atrophoderma vermiculatum, atrophodermia reticulata symmetrica faciei, atrophodermia ulerythematosa, atrophodermie vermiculée des joues avec kératoses folliculaires, folliculitis ulerythema reticulata, folliculitis ulerythematous reticulata, folliculitis ulerythemosa, honeycomb atrophy, ulerythema acneforme, ulerythema acneiforme) Autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome Bart syndrome Bazex–Dupré–Christol syndrome (Bazex syndrome, follicular atrophoderma and basal cell carcinomas) Beare–Stevenson cutis gyrata syndrome Bloom syndrome (Bloom–Torre–Machacek syndrome) Blue rubber bleb nevus syndrome Brittle hair–intellectual impairment–decreased fertility–short stature syndrome Cantú syndrome Cardio-facio-cutaneous syndrome (cardiofaciocutaneous syndrome) Cartilage–hair hypoplasia (McKusick type metaphyseal chondrodysplasia) Cerebral dysgenesis–neuropathy–ichthyosis–keratoderma syndrome Childhood tumor syndrome Chondrodysplasia punctata Cicatricial junctional epidermolysis bullosa Craniosynostosis–anal anomalies–porokeratosis syndrome Cockayne syndrome Colobomas of the eye–heart defects–ichthyosiform dermatosis–mental retardation–ear defects syndrome (CHIME syndrome, Zunich neuroectodermal syndrome, Zunich–Kaye syndrome) Congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome (CHILD syndrome) Conradi–Hünermann syndrome (Conradi–Hünermann–Happle syndrome, Happle syndrome, X-linked dominant chondrodysplasia punctata) Costello syndrome Cronkhite–Canada syndrome Crouzon syndrome Cutis verticis gyrata Darier's disease (Darier–White disease, dyskeratosis follicularis, keratosis follicularis) DeSanctis–Cacchione syndrome Disseminated superficial actinic porokeratosis Disseminated superficial porokeratosis Dolichol kinase deficiency Dominant dystrophic epidermolysis bullosa Dyskeratosis congenita (Zinsser–Cole–Engman syndrome) Dystrophic epidermolysis bullosa Ectodermal dysplasia Ectodermal dysplasia with corkscrew hairs Ectrodactyly–ectodermal dysplasia–cleft syndrome (EEC syndrome, split hand–split foot–ectodermal dysplasia–cleft syndrome) Epidermolysis bullosa herpetiformis (Dowling–Meara epidermolysis bullosa simplex) Epidermolysis bullosa simplex Epidermolysis bullosa simplex of Ogna Epidermolysis bullosa simplex with mottled pigmentation Epidermolysis bullosa simplex with muscular dystrophy Epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma, bullous ichthyosiform erythroderma) Erythrokeratodermia with ataxia (Giroux–Barbeau syndrome) Familial benign chronic pemphigus (familial benign pemphigus, Hailey–Hailey disease) Fanconi syndrome (familial pancytopenia, familial panmyelophthisis) Fibrodysplasia ossificans progressiva Focal dermal hypoplasia (Goltz syndrome) Follicular atrophoderma Franceschetti–Klein syndrome (mandibulofacial dysostosis) Gardner's syndrome (familial colorectal polyposis) Gastrocutaneous syndrome Generalized atrophic benign epidermolysis bullosa Generalized epidermolysis bullosa simplex (Koebner variant of generalized epidermolysis bullosa simplex) Generalized trichoepithelioma Giant axonal neuropathy with curly hair Gingival fibromatosis with hypertrichosis Haber syndrome Hallerman–Streiff syndrome Harlequin-type ichthyosis (harlequin baby, harlequin fetus, harlequin ichthyosis, ichthyosis congenita, ichthyosis congenita gravior) Hay–Wells syndrome (AEC syndrome, ankyloblepharon filiforme adnatum–ectodermal dysplasia–cleft palate syndrome, ankyloblepharon–ectodermal defects–cleft lip and palate syndrome, ankyloblepharon–ectodermal dysplasia–clefting syndrome) Hereditary sclerosing poikiloderma Heterochromia iridum Holocarboxylase synthetase deficiency Hypohidrotic ectodermal dysplasia (anhidrotic ectodermal dysplasia, Christ–Siemens–Touraine syndrome) Hypotrichosis–acro-osteolysis–onychogryphosis–palmoplantar keratoderma–periodontitis syndrome Hypotrichosis–lymphedema–telangiectasia syndrome Ichthyosis–brittle hair–impaired intelligence–decreased fertility–short stature syndrome (IBIDS syndrome, sulfur-deficient brittle hair syndrome, Tay's syndrome, trichothiodystrophy, trichothiodystrophy with ichthyosis) Ichthyosis bullosa of Siemens (ichthyosis exfoliativa) Ichthyosis follicularis (ichthyosis follicularis with alopecia and photophobia syndrome) Ichthyosis linearis circumflexa Ichthyosis prematurity syndrome Ichthyosis vulgaris (autosomal dominant ichthyosis, ichthyosis simplex) Ichthyosis with confetti Neonatal ichthyosis–sclerosing cholangitis syndrome (ichthyosis–sclerosing cholangitis syndrome, NISCH syndrome) Incontinentia pigmenti achromians (hypomelanosis of Ito) Immune dysfunction–polyendocrinopathy–enteropathy–X-linked syndrome Jaffe–Campanacci syndrome Johanson–Blizzard syndrome Johnson–McMillin syndrome Joubert syndrome Junctional epidermolysis bullosa Junctional epidermolysis bullosa gravis (epidermolysis bullosa letalis, Herlitz disease, Herlitz epidermolysis bullosa, Herlitz syndrome, lethal junctional epidermolysis bullosa) Junctional epidermolysis bullosa with pyloric atresia Kabuki syndrome (Kabuki makeup syndrome, Niikawa–Kuroki syndrome) Keratolytic winter erythema (erythrokeratolysis hiemalis, Oudtshoorn disease, Oudtshoorn skin) Keratosis follicularis spinulosa decalvans (Siemens-1 syndrome) Keratosis linearis with ichthyosis congenita and sclerosing keratoderma syndrome Keratosis pilaris atrophicans faciei (folliculitis rubra, keratosis pilaris rubra atrophicans faciei, lichen pilare, lichen pilaire ou xerodermie pilaire symmetrique de la face, ulerythema ophryogenes, xerodermi pilaire symmetrique de la face) Keratosis pilaris Kindler syndrome (acrokeratotic poikiloderma, bullous acrokeratotic poikiloderma of Kindler and Weary, congenital poikiloderma with blisters and keratoses, congenital poikiloderma with bullae and progressive cutaneous atrophy, hereditary acrokeratotic poikiloderma, hyperkeratosis–hyperpigmentation syndrome, Weary–Kindler syndrome) Klinefelter syndrome Klippel–Feil syndrome Lamellar ichthyosis (collodion baby) Legius syndrome (neurofibromatosis type 1-like syndrome) Lelis syndrome Lenz–Majewski syndrome Leschke syndrome Lethal acantholytic epidermolysis bullosa Lhermitte–Duclos disease Linear and whorled nevoid hypermelanosis (linear nevoid hyperpigmentation, progressive cribriform and zosteriform hyperpigmentation, reticulate and zosteriform hyperpigmentation, reticulate hyperpigmentation of Iijima and Naito and Uyeno, zebra-like hyperpigmentation in whorls and streaks, zebra-line hyperpigmentation) Linear Darier disease (acantholytic dyskeratotic epidermal nevus) Linear porokeratosis Localized epidermolysis bullosa simplex (Weber–Cockayne syndrome, Weber–Cockayne variant of generalized epidermolysis bullosa simplex) Mandibuloacral dysplasia Marinesco–Sjögren syndrome McCune–Albright syndrome McCusick syndrome Metageria Microphthalmia–dermal aplasia–sclerocornea syndrome Mitis junctional epidermolysis bullosa (nonlethal junctional epidermolysis bullosa) Mitochondrial myopathy–encephalopathy–lactic acidosis–stroke syndrome Multiple lentigines syndrome (cardiocutaneous syndrome, Gorlin syndrome II, lentiginosis profusa syndrome, LEOPARD syndrome, progressive cardiomyopathic lentiginosis) Multiple pterygium syndrome Multiple sulfatase deficiency (Austin disease, mucosulfatidosis) Naegeli–Franceschetti–Jadassohn syndrome (chromatophore nevus of Naegeli) Netherton syndrome Neurofibromatosis type 1 (von Recklinghausen's disease) Neurofibromatosis type 3 (neurofibromatosis mixed type) Neurofibromatosis type 4 (neurofibromatosis variant type) Neutral lipid storage disease (Dorfman–Chanarin syndrome) Nonbullous congenital ichthyosiform erythroderma (congenital ichthyosiform erythroderma) Noonan syndrome Oculocerebrocutaneous syndrome (Delleman–Oorthuys syndrome) Oculodentodigital dysplasia Odonto-tricho-ungual-digital-palmar syndrome Oliver–McFarlane syndrome Orofaciodigital syndrome Pachydermoperiostosis (idiopathic hypertrophic osteoathorpathy, Touraine–Solente–Gole syndrome) Peeling skin syndrome (acral peeling skin syndrome, continual peeling skin syndrome, familial continual skin peeling, idiopathic deciduous skin, keratolysis exfoliativa congenita) Pfeiffer syndrome Photosensitivity–ichthyosis–brittle sulfur-deficient hair–impaired intelligence–decreased fertility–short stature syndrome Pityriasis rotunda (pityriasis circinata, tinea circinata) Plate-like osteoma cutis Plaque-type porokeratosis (classic porokeratosis, porokeratosis of Mibelli) Polyneuropathy–organomegaly–endocrinopathy–monoclonal gammopathy–skin changes syndrome (Crow–Fukase syndrome) Polyostotic fibrous dysplasia (Albright's disease) Popliteal pterygium syndrome Porokeratosis Porokeratosis palmaris et plantaris disseminata Prader–Willi syndrome Progeria (Hutchinson–Gilford progeria syndrome, Hutchinson–Gilford syndrome, progeria syndrome) Progressive osseous heteroplasia Progressive symmetric erythrokeratodermia (erythrokeratodermia progressiva symmetrica) Proteus syndrome Proteus-like syndrome Punctate porokeratosis Rapp–Hodgkin syndrome (Rapp–Hodgkin ectodermal dysplasia syndrome) Recessive dystrophic epidermolysis bullosa (Hallopeau–Siemens variant of epidermolysis bullosa, Hallopeau–Siemens disease) Refsum's disease (heredopathia atactica polyneuritiformis, phytanic acid storage disease) Relapsing linear acantholytic dermatosis Restrictive dermopathy Rhizomelic chondrodysplasia punctata (autosomal recessive chondrodysplasia punctata type 1, chondrodystrophia calcificans punctata, peroxisomal biogenesis disorder complementation group 11) Rombo syndrome Rothmund–Thomson syndrome (poikiloderma congenitale) Rud syndrome Say syndrome Scalp–ear–nipple syndrome (Finlay–Marks syndrome) Schindler disease (Kanzaki disease, alpha-N-acetylgalactosaminidase deficiency) Schinzel–Giedion syndrome Scleroatrophic syndrome of Huriez (Huriez syndrome, palmoplantar keratoderma with scleroatrophy, palmoplantar keratoderma with sclerodactyly, scleroatrophic and keratotic dermatosis of the limbs, sclerotylosis) Segmental neurofibromatosis Senter syndrome (Desmons' syndrome) Shabbir syndrome (laryngo–onycho–cutaneous syndrome) Silver–Russell syndrome Sjögren–Larsson syndrome Skin fragility syndrome (plakophilin 1 deficiency) Smith–Lemli–Opitz syndrome Sturge–Weber syndrome Supernumerary nipples–uropathies–Becker's nevus syndrome Terminal osseous dysplasia with pigmentary defects Tooth and nail syndrome (hypodontia with nail dysgenesis, Witkop syndrome) Townes–Brocks syndrome Transient bullous dermolysis of the newborn Treacher Collins syndrome (Treacher Collins–Franceschetti syndrome) Tricho–dento–osseous syndrome Tricho–rhino–phalangeal syndrome Tuberous sclerosis (Bourneville disease, epiloia) Turner syndrome Ulnar–mammary syndrome Van Der Woude syndrome Von Hippel–Lindau syndrome Watson syndrome Werner syndrome (adult progeria) Westerhof syndrome Whistling syndrome (craniocarpotarsal syndrome, distal arthrogryposis type 2, Freeman–Sheldon syndrome, Windmill–Vane–Hand syndrome) Wilson–Turner syndrome Wolf–Hirschhorn syndrome (4p- syndrome) X-linked ichthyosis (steroid sulfatase deficiency, X-linked recessive ichthyosis) X-linked recessive chondrodysplasia punctata Xeroderma pigmentosum (Cockayne syndrome complex) XXYY genotype Zimmermann–Laband syndrome
Chocolate is a food made from roasted and ground cocoa beans. It can be a liquid, solid, or paste. It is eaten on its own and used to flavor other foods. Cocoa beans are the processed seeds of the cacao tree (Theobroma cacao). They are usually fermented to develop the flavor, then dried, cleaned, and roasted. The shell is removed to reveal nibs, which are ground to chocolate liquor (unadulterated chocolate in rough form.) The liquor can be further processed into cocoa butter and cocoa powder, or shaped and sold as unsweetened baking chocolate. By adding sugar, sweetened chocolates are produced, which can be sold simply as dark chocolate, or, with the addition of milk, can be made into milk chocolate. Making chocolate with only cocoa butter and milk produces white chocolate. Chocolate is one of the most popular food types and flavors in the world, and many foodstuffs include chocolate, particularly desserts, including ice creams, cakes, mousse, and cookies. Many candies are filled with or coated with sweetened chocolate. Chocolate bars, either made of solid chocolate or other ingredients coated in chocolate, are eaten as snacks. Gifts of chocolate molded into different shapes (such as eggs, hearts, and coins) are traditional on certain holidays, including Christmas, Easter, Valentine's Day, Hanukkah and Eid al-Fitr. Chocolate is also used in cold and hot beverages, such as chocolate milk, hot chocolate and chocolate liqueur. The cacao tree was first used as a source for food in what is today Ecuador at least 5,300 years ago.
=== Liberal Leaders in the House of Lords === Granville Leveson-Gower, 2nd Earl Granville (1859–1865) John Russell, 1st Earl Russell (1865–1868) Granville Leveson-Gower, 2nd Earl Granville (1868–1891) John Wodehouse, 1st Earl of Kimberley (1891–1894) Archibald Primrose, 5th Earl of Rosebery (1894–1896) John Wodehouse, 1st Earl of Kimberley (1896–1902) John Spencer, 5th Earl Spencer (1902–1905) George Robinson, 1st Marquess of Ripon (1905–1908) Robert Crewe-Milnes, 1st Marquess of Crewe (1908–1923) Edward Grey, 1st Viscount Grey of Fallodon (1923–1924) William Lygon, 7th Earl Beauchamp (1924–1931) Rufus Isaacs, 1st Marquess of Reading (1931–1936) Robert Crewe-Milnes, 1st Marquess of Crewe (1936–1944) Herbert Samuel, 1st Viscount Samuel (1944–1955) Philip Rea, 2nd Baron Rea (1955–1967) Frank Byers (1967–1984) Nancy Seear, Baroness Seear (1984–1989)
=== Monitoring of activists === The Stratfor email leak revealed that Dow Chemical had engaged Stratfor to spy on the public and personal lives of activists involved in the Bhopal disaster, including the Yes Men. E-mails to Dow representatives from hired security analysts list the YouTube videos liked, Twitter and Facebook posts made and the public appearances of these activists. Journalists, filmmakers and authors who were investigating Bhopal and covering the issue of ongoing contamination, such as Jack Laurenson and Max Carlson, were also placed under surveillance. Stratfor released a statement condemning the revelation by Wikileaks while neither confirming nor denying the accuracy of the reports and would only state that it had acted within the bounds of the law. Dow Chemical also refrained from commenting on the matter. Ingrid Eckerman, a member of the International Medical Commission on Bhopal, has been denied a visa to visit India.
Sources: en.wikipedia.org
Fourier-transform ion cyclotron resonance mass spectrometry (also known as Fourier-transform mass spectrometry) is a type of mass spectrometry used for determining the mass-to-charge ratio (m/z) of ions based on the cyclotron frequency of the ions in a fixed magnetic field. The ions are trapped in a Penning trap where they are excited to a larger cyclotron radius by an oscillating electric field perpendicular to the magnetic field. The excitation also results in the ions moving in phase (in a packet). The signal is detected as an image current on a pair of plates which the packet of ions passes close to as they cyclotron. The resulting signal is called a free induction decay (fid), transient or interferogram that consists of a superposition of sine waves. The useful signal is extracted from this data by performing a Fourier transform to give a mass spectrum. Single ions can be investigated in a Penning trap held at a temperature of 4 K. For this the ring electrode is segmented and opposite electrodes are connected to a superconducting coil and the source and the gate of a field-effect transistor. The coil and the parasitic capacitances of the circuit form a LC circuit with a Q of about 50 000. The LC circuit is excited by an external electric pulse. The segmented electrodes couple the motion of the single electron to the LC circuit. Thus the energy in the LC circuit in resonance with the ion slowly oscillates between the many electrons (10000) in the gate of the field effect transistor and the single electron.
== Toxicity == The recommended therapeutic dose is 80-100 mg/m2 body area. Optimal dosage is determined based on measurements of unbound platinum concentration following intravenous infusion, combined with rate of creatine clearance as an assessment of renal function using Ishibashi’s formula: DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47 The exact mechanism of uptake into the cell is unknown, with information being considerably less available compared to cisplatin. What is known is that nedaplatin does not interact with the Oct2 or apical multidrug and toxin extrusion transporter (MATE) transporters, potentially explaining the difference in nephrotoxicity due to reduced accumulation in the proximal tubules of the kidney. Toxicogenomics has helped elucidate some of the mechanisms behind nephrotoxicity, where oxidative stress has been shown to deregulate gene expression via Hmox1 and other genes.
=== Regulations === Because of the adverse effects of cadmium on the environment and human health, the supply and use of cadmium is restricted in Europe under the REACH Regulation. The EFSA Panel on Contaminants in the Food Chain specifies that 2.5 μg/kg body weight is a tolerable weekly intake for humans. The Joint FAO/WHO Expert Committee on Food Additives has declared 7 μg/kg body weight to be the provisional tolerable weekly intake level. The state of California requires a food label to carry a warning about potential exposure to cadmium on products such as cocoa powder. The European Commission has put in place the EU regulation (2019/1009) on fertilizing products (EU, 2019), adopted in June 2019 and fully applicable as of July 2022. It sets a Cd limit value in phosphate fertilizers to 60 mg kg−1 of P2O5. The U.S. Occupational Safety and Health Administration (OSHA) has set the permissible exposure limit (PEL) for cadmium at a time-weighted average (TWA) of 0.005 ppm. The National Institute for Occupational Safety and Health (NIOSH) has not set a recommended exposure limit (REL) and has designated cadmium as a known human carcinogen. The IDLH (immediately dangerous to life and health) level for cadmium is 9 mg/m3.
Sources: en.wikipedia.org
=== Photodegradation === Additionally, DBNPA is prone to light-induced degradation, especially when exposed to ultraviolet (UV) radiation. Photocatalytic breakdown leads to debromination and the formation of less reactive intermediates, further accelerating its degradation in aqueous systems.
The amount of YAN that winemakers will see in their grape musts depends on a number of components including grape variety, rootstock, vineyard soils and viticultural practices (such as the use of fertilizers and canopy management) as well as the climate conditions of particular vintages.
IR4: Infrared detector for composition and concentration measurements in polyolefins for gel permeation chromatography (GPC/SEC), HPLC, TREF, etc. IR5: an infrared detector for highly demanding applications in Polymer Char instruments such as GPC-IR, HPLC, CFC and other separation techniques. Part of the techniques and instruments were developed with Petrochemical companies and Research Institutes from United States, Belgium, Finland, Germany and Japan. The company supplies in over 35 countries around the globe Analytical Services for Polymer characterization.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.